Novel Antiangiogenic Effects of the Bisphosphonate Compound Zoledronic Acid

10.1016/S1050-1738(01)00152-9

Asahara, 1999, Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization., Circ Res, 85, 221, 10.1161/01.RES.85.3.221

Bellahcène, 2000, Bone sialoprotein mediates human endothelial cell attachment and migration and promotes angiogenesis., Circ Res, 86, 885, 10.1161/01.RES.86.8.885

Berenson, 1998, Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group., J Clin Oncol, 16, 593, 10.1200/JCO.1998.16.2.593

10.1146/annurev.med.50.1.237

Boissier S Colombel M Delmas P Cabon C Clézardin P (2002) Zoledronic acid inhibits in vivo experimental angiogenesis (abstract B3). Bone 30:38S.

Boissier, 1997, Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineralized bone extracellular matrices., Cancer Res, 57, 3890

Bonjean K Bellahcène A Locigno R Castronovo V (2002) Zoledronic acid inhibits human endothelial cell adhesion to vitronectin and selectively alters the expression of extracellular matrix cell surface receptors (abstract B4). Bone 30:38S.

Boonekamp, 1986, Two modes of action of bisphosphonates on osteoclastic resorption of mineralized matrix., Bone Miner, 1, 27

10.1007/s002239900519

Croucher P Hijzen A Shipman C Perry M Lippitt J Green J Van Camp B Vanderkerken K (2001) Zoledronic acid inhibits the development of osteolytic bone disease and increases disease free survival in a murine model of multiple myeloma. Blood 98:160a.

10.1056/NEJM199808063390601

Fleisch, 1997, Bisphosphonates: mechanisms of action and clinical use in osteoporosis—an update., Horm Metab Res, 29, 145, 10.1055/s-2007-979008

Fleisch H (1998) Bisphosphonates: mechanisms of action. Endocr Rev 19:80–100.

10.1038/nm0195-27

Hortobagyi, 1998, Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group., J Clin Oncol, 16, 2038, 10.1200/JCO.1998.16.6.2038

Hughes, 1995, Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo., J Bone Miner Res, 10, 1478, 10.1002/jbmr.5650101008

Legler, 2001, Superactivation of integrin alphavbeta3 by low antagonist concentrations., J Cell Sci, 114, 1545, 10.1242/jcs.114.8.1545

10.1359/jbmr.1998.13.4.581

10.1083/jcb.97.5.1648

10.1097/00007890-199906270-00020

10.1053/joca.2001.0506

10.1359/jbmr.2001.16.11.2027

Podworny, 1999, Partial chondroprotective effect of zoledronate in a rabbit model of inflammatory arthritis., J Rheumatol, 26, 1972

Rosen, 2001, Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial., Cancer J, 7, 377

Saarto, 2001, Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5-year results of a randomized controlled trial., J Clin Oncol, 19, 10, 10.1200/JCO.2001.19.1.10

Senaratne, 2000, Bisphosphonates induce apoptosis in human breast cancer cell lines., Br J Cancer, 82, 1459, 10.1054/bjoc.1999.1131

10.1080/028418600750063587

.

Wood, 2000, PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration., Cancer Res, 60, 2178

10.1046/j.1365-2141.2002.03257.x

Zimolo, 1995, Acid extrusion is induced by osteoclast attachment to bone. Inhibition by alendronate and calcitonin., J Clin Investig, 96, 2277, 10.1172/JCI118283